Focused On-demand Library for Unconventional myosin-VIIa

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q13402

UPID:

MYO7A_HUMAN

Alternative names:

Alternative UPACC:

Q13402; B9A011; F8VUN5; P78427; Q13321; Q14785; Q92821; Q92822

Background:

Unconventional myosin-VIIa plays a pivotal role in cellular movements and sensory functions. It is crucial for the renewal of outer photoreceptor disks in the retina, aiding in vision, and supports the organization of cochlear hair cell bundles in the inner ear, essential for hearing. This protein's involvement in vesicle trafficking suggests a broad impact on cellular health and function.

Therapeutic significance:

Given its association with Usher syndrome 1B, autosomal recessive deafness 2, and autosomal dominant deafness 11, targeting unconventional myosin-VIIa offers a promising avenue for treating sensorineural hearing loss and retinitis pigmentosa. Understanding its role could open doors to potential therapeutic strategies.